Clinical Trial Now Recruiting Dogs With Histiocytic Sarcoma

Last August the Morris Animal Foundation announced a new clinical trial **funded by the BMDCA** to test the effectiveness of a new treatment - Trametinib - for histiocytic sarcoma:

https://www.morrisanimalfoundation.org/article/new-clinical-trial-assess-canine-cancer-treatment-histiocytic-sarcoma

That trial is now accepting patients at the following four universities. Each has websites describing what dogs may participate, and what dogs are not eligible.

- University of Florida
  https://research.vetmed.ufl.edu/phase-ii-open-label-non-randomized-multicenter-clinical-trial-of-trametinib-for-dogs-with-histiocytic-sarcoma/
- Virginia Tech
  https://research.vetmed.vt.edu/clinical-trials/current-studies/trametinib.html
- Michigan State University
  https://cvm.msu.edu/hospital/veterinarians/clinical-trials/phase-ii-open-label-non-randomized-multicenter-clinical-trial-of-trametinib-for-dogs-with-histiocytic-sarcoma
- University of Wisconsin *website to be available soon.*

The drug and physical exam rechecks and any routine tests or imaging needed at those recheck visits are free of cost and must completed at the trial site.

Eligibility criteria:

* Dogs of any age, weight, sex, or breed with a cytological or histological diagnosis of histiocytic sarcoma
* Dogs with measurable tumors (primary or metastatic)
* Dogs with an estimated life expectancy of >4 weeks
* Participation in the study will be offered when conventional therapy is no longer effective or is declined by the dog's client-caregiver.
* Signed informed consent and consent to necropsy will be obtained at time of enrollment.
* No prior chemotherapy within a minimum 2-week period
* No prior radiation therapy within a minimum 1-month period
* Dogs with adequate organ and marrow function and without serious systemic disorders that could compromise the patient's health
* Dogs with a prior or concurrent cancer whose prognosis or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen

Pat Long,
BMDCA Health Committee Chair